A Highly Selective and Sensitive LC–MS/HRMS Assay for Quantifying Coproporphyrins as Organic Anion-Transporting Peptide Biomarkers

References

• Rodrigues AD , TaskarKS, KusuharaH, SugiyamaY. Endogenous probes for drug transporters: balancing vision with reality. Clin. Pharmacol. Ther. doi: 10.1002/cpt.749 (2017) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK , MeyersonG, HagbjorkAL, JuricS, TereliusY. A strategy for early-risk predictions of clinical drug–drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors. Xenobiotica doi: https://doi.org/10.1080/00,498254.2017.13,23136 1–9 (2017) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Fowler S , MorcosPN, ClearyYet al. Progress in prediction and interpretation of clinically relevant metabolic drug–drug interactions: a minireview illustrating recent developments and current opportunities. Curr. Pharmacol. Rep. 3 (1), 36–49 (2017).
   PubMedGoogle Scholar
• Kumar S , SharmaR, RoychowdhuryA. Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective. Curr. Med. Chem. 19 (21), 3605–3621 (2012).
   PubMed Web of Science ®Google Scholar
• Yoshida K , ZhaoP, ZhangLet al. In vitro-Ii vivo extrapolation of metabolism- and transporter-mediated drug–drug interactions – overview of basic prediction methods. J. Pharm. Sci. 106 (9), 2209–2213 (2017).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan J , YoshidaK, AryaV, ZhangL. Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1. J. Clin. Pharmacol. 56 (Suppl. 7), S59–S72 (2016).
   PubMedGoogle Scholar
• Bednarczyk D , BoiselleC. Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III. Xenobiotica46 (5), 457–466 (2016).
   PubMed Web of Science ®Google Scholar
• Hayashi Y , UdagawaM. High-pressure liquid chromatography combined with fluorescence detection and solvent extraction for simultaneous determination of coproporphyrins I and III in human urine. Talanta30 (5), 368–370 (1983).
   PubMed Web of Science ®Google Scholar
• Sakai T , NiinumaY, YanagiharaS, UshioK. Liquid-chromatographic separation and determination of coproporphyrins I and III in urine. Clin. Chem. 29 (2), 350–353 (1983).
   PubMed Web of Science ®Google Scholar
• Shen H , ChenW, DrexlerDMet al. Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects. Drug Metab. Dispos. 45 (8), 908–919 (2017).
   PubMed Web of Science ®Google Scholar
• Shen H , DaiJ, LiuTet al. Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. J. Pharmacol. Exp. Ther. 357 (2), 382–393 (2016).
   PubMed Web of Science ®Google Scholar
• Lai Y , MandlekarS, ShenHet al. Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug–drug interactions mediated by organic anion transporting polypeptide inhibition. J. Pharmacol. Exp. Ther. 358 (3), 397–404 (2016).
   PubMed Web of Science ®Google Scholar
• Minato K , SuzukiM, NagaoH, SuzukiR, OchiaiH. Development of analytical method for simultaneous determination of five rodent unique bile acids in rat plasma using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1002, 399–410 (2015).
   PubMed Web of Science ®Google Scholar
• Ito S , KusuharaH, KumagaiYet al. N-methylnicotinamide is an endogenous probe for evaluation of drug–drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin. Pharmacol. Ther. 92 (5), 635–641 (2012).
   PubMed Web of Science ®Google Scholar
• Lechner C , IshiguroN, FukuharaAet al. Impact of experimental conditions on the evaluation of interactions between multidrug and toxin extrusion proteins and candidate drugs. Drug Metab. Dispos. 44 (8), 1381–1389 (2016).
   PubMed Web of Science ®Google Scholar
• Omae K , SakuraiH, HigashiT, HosodaK, TeruyaK, SuzukiY. Reevaluation of urinary excretion of coproporphyrins in lead-exposed workers. Int. Arch. Occup. Environ. Health60 (2), 107–110 (1988).
   PubMed Web of Science ®Google Scholar
• Garcia-Vargas GG , Hernandez-ZavalaA. Urinary porphyrins and heme biosynthetic enzyme activities measured by HPLC in arsenic toxicity. Biomed. Chromatogr. 10 (6), 278–284 (1996).
   PubMed Web of Science ®Google Scholar
• Abe K , KonakaR. Quantification of urinary porphyrins by liquid chromatography after oxidation of porphyrinogens. Clin. Chem. 35 (8), 1619–1622 (1989).
   PubMed Web of Science ®Google Scholar
• Bozek P , HuttaM, HrivnakovaB. Rapid analysis of porphyrins at low ng/l and microg/l levels in human urine by a gradient liquid chromatography method using octadecylsilica monolithic columns. J. Chromatogr. A1084 (1–2), 24–32 (2005).
   PubMed Web of Science ®Google Scholar
• Respaud R , Benz-De BretagneI, BlascoH, HulotJS, LechatP, Le GuellecC. Quantification of coproporphyrin isomers I and III in urine by HPLC and determination of their ratio for investigations of multidrug resistance protein 2 (MRP2) function in humans. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877 (30), 3893–3898 (2009).
   PubMed Web of Science ®Google Scholar
• Jacob K , DossMO. Composition of urinary coproporphyrin isomers I-IV in human porphyrias. Eur. J. Clin. Chem. Clin. Biochem. 31 (10), 617–624 (1993).
   PubMedGoogle Scholar
• Jacob K , EgelerE, GrossU, DossMO. Investigations on the formation of urinary coproporphyrin isomers I-IV in 5-aminolevulinic acid dehydratase deficiency porphyria, acute lead intoxication and after oral 5-aminolevulinic acid loading. Clin. Biochem. 32 (2), 119–123 (1999).
   PubMed Web of Science ®Google Scholar
• To-Figueras J , OzallaD, MateuCH. Long-standing changes in the urinary profile of porphyrin isomers after clinical remission of porphyria cutanea tarda. Ann. Clin. Lab. Sci. 33 (3), 251–256 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen C , KirschRE, MooreMR. Porphobilinogen deaminase and the synthesis of porphyrin isomers in the Dubin-Johnson syndrome. S. Afr. Med. J. 70 (1), 36–39 (1986).
   PubMed Web of Science ®Google Scholar
• Jacob K , EgelerE, HennelB, LuppaP. Coproporphyrin isomers II and IV are normal constituents of human urine. J. Clin. Chem. Clin. Biochem. 27 (9), 659–661 (1989).
   PubMedGoogle Scholar
• Jacob K , EgelerE, HennelB, LuppaP, NeumeierD. The isomer ratios of urinary coproporphyrins I–IV are pH-dependent. Eur. J. Clin. Chem. Clin. Biochem. 29 (2), 115–119 (1991).
   PubMedGoogle Scholar
• Xia YQ , LauJ, OlahT, JemalM. Targeted quantitative bioanalysis in plasma using liquid chromatography/high-resolution accurate mass spectrometry: an evaluation of global selectivity as a function of mass resolving power and extraction window, with comparison of centroid and profile modes. Rapid Commun. Mass Spectrom. 25 (19), 2863–2878 (2011).
   PubMed Web of Science ®Google Scholar
• Wei C , GraceJEJr., ZvyagaTA, DrexlerDM. Utility of high-resolution accurate MS to eliminate interferences in the bioanalysis of ribavirin and its phosphate metabolites. Bioanalysis4 (15), 1895–1905 (2012).
   PubMed Web of Science ®Google Scholar
• Huang MQ , LinZJ, WengN. Applications of high-resolution MS in bioanalysis. Bioanalysis5 (10), 1269–1276 (2013).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , JemalM, RamagiriSet al. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J. Mass Spectrom. 46 (6), 595–601 (2011).
   PubMed Web of Science ®Google Scholar
• Gomez-Perez ML , Romero-GonzalezR, Martinez VidalJL, Garrido FrenichA. Analysis of veterinary drug and pesticide residues in animal feed by high-resolution mass spectrometry: comparison between time-of-flight and Orbitrap. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 32 (10), 1637–1646 (2015).
   PubMed Web of Science ®Google Scholar
• Lee MS , ZhuM. Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications. Wiley, Hoboken, NJ, USA (2011).
   Google Scholar
• Hopfgartner G , TonoliD, VaresioE. High-resolution mass spectrometry for integrated qualitative and quantitative analysis of pharmaceuticals in biological matrices. Anal. Bioanal. Chem. 402 (8), 2587–2596 (2012).
   PubMed Web of Science ®Google Scholar
• Andrews GL , SimonsBL, YoungJB, HawkridgeAM, MuddimanDC. Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Anal. Chem. 83 (13), 5442–5446 (2011).
   PubMed Web of Science ®Google Scholar
• FDA C . Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Rockville, MD, USA (2001).
   Google Scholar
• Yuan L , LuoY, KandoussiH, JiQC. A simple, fast, sensitive and robust LC–MS/MS bioanalytical assay for evaluating 7alpha-hydroxy-4-cholesten-3-one biomarker in a clinical program. Bioanalysis8 (23), 2445–2455 (2016).
   PubMed Web of Science ®Google Scholar
• Korfmacher WA . Foundation review: principles and applications of LC–MS in new drug discovery. Drug Discov. Today10 (20), 1357–1367 (2005).
   PubMed Web of Science ®Google Scholar
• Korfmacher WA . Principles and applications of LC–MS in new drug discovery. Drug Discov. Today10 (20), 1357–1367 (2005).
   PubMed Web of Science ®Google Scholar
• Penner N , RamanathanR, Zgoda-PolsJ, ChowdhuryS. Quantitative determination of hippuric and benzoic acids in urine by LC–MS/MS using surrogate standards. J. Pharm. Biomed. Anal. 52 (4), 534–543 (2010).
   PubMed Web of Science ®Google Scholar
• Thakare R , ChhonkerYS, GautamN, AlamoudiJA, AlnoutiY. Quantitative analysis of endogenous compounds. J. Pharm. Biomed. Anal. 128, 426–437 (2016).
   PubMed Web of Science ®Google Scholar
• Jones BR , SchultzGA, EcksteinJA, AckermannBL. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis4 (19), 2343–2356 (2012).
   PubMed Web of Science ®Google Scholar
• Li W , CohenLH. Quantitation of endogenous analytes in biofluid without a true blank matrix. Anal. Chem. 75 (21), 5854–5859 (2003).
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration . Guidance for Industry-Bioanalytical Method Validation. (2001). www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf
   Google Scholar
• Nedderman AN . Metabolites in safety testing: metabolite identification strategies in discovery and development. Biopharm. Drug Dispos. 30 (4), 153–162 (2009).
   PubMed Web of Science ®Google Scholar
• Bower J , FastD, GarofoloFet al. 8th GCC: consolidated feedback to US FDA on the 2013 draft FDA guidance on bioanalytical method validation. Bioanalysis6 (22), 2957–2963 (2014).
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration . Guidance for industry M3(R2). Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (2010). www.fda.gov/downloads/drugs/guidances/ucm073246.pdf
   Google Scholar
• Zimmer D . New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR. Bioanalysis6 (1), 13–19 (2014).
   PubMed Web of Science ®Google Scholar
• Cummings J , RaynaudF, JonesL, SugarR, DiveC. Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br. J. Cancer103 (9), 1313–1317 (2010).
   PubMed Web of Science ®Google Scholar
• Booth B , ArnoldME, DesilvaBet al. Workshop report: Crystal City V – quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance. AAPS J. 17 (2), 277–288 (2015).
   PubMed Web of Science ®Google Scholar
• Song A , LeeA, GarofoloFet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part II - hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis8 (23), 2457–2474 (2016).
   PubMed Web of Science ®Google Scholar
• Chambers E , Wagrowski-DiehlDM, LuZ, MazzeoJR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852 (1–2), 22–34 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang H , CaoH, ZhangY, FastDM. Systematic evaluation of supported liquid extraction in reducing matrix effect and improving extraction efficiency in LC–MS/MS based bioanalysis for 10 model pharmaceutical compounds. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 891–892, 71–80 (2012).
   PubMed Web of Science ®Google Scholar
• Ranasinghe A , RamanathanR, JemalM, D’arienzoCJ, HumphreysWG, OlahTV. Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS. Bioanalysis4 (5), 511–528 (2012).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , KorfmacherW. The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena. Bioanalysis4 (5), 467–469 (2012).
   PubMed Web of Science ®Google Scholar
• Aratyn-Schaus Y , RamanathanR. Advances in high resolution mass spectrometry and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis8 (16), 1645–1662 (2016).
   PubMed Web of Science ®Google Scholar
• Grafmuller L , WeiC, RamanathanR, BarlettaF, SteenwykR, TweedJ. Unconjugated payload quantification and DAR characterization of antibody-drug conjugates using high resolution mass spectrometry (HRMS). Bioanalysis8 (16), 1663–1678 (2016).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , KorfmacherW. HRMS or HRAMS. Bioanalysis8 (16), 1639–1640 (2016).
   PubMed Web of Science ®Google Scholar
• Xia YQ , LauJ, OlahT, JemalM. Targeted quantitative bioanalysis in plasma using liquid chromatography/high-resolution accurate mass spectrometry: an evaluation of global selectivity as a function of mass resolving power and extraction window, with comparison of centroid and profile modes. Rapid Commun. Mass Spectrom. 25 (19), 2863–2878 (2011).
   PubMed Web of Science ®Google Scholar
• Sturm RM , JonesBR, MulvanaDE, LowesS. HRMS using a Q-Exactive series mass spectrometer for regulated quantitative bioanalysis: how, when, and why to implement. Bioanalysis8 (16), 1709–1721 (2016).
   PubMed Web of Science ®Google Scholar
• Hamelin EI , BraggW, ShanerRL, SwaimLL, JohnsonRC. Comparison of high-resolution and tandem mass spectrometry for the analysis of nerve agent metabolites in urine. Rapid Commun. Mass Spectrom. 27 (15), 1697–1704 (2013).
   PubMed Web of Science ®Google Scholar
• Van De Merbel NC , BronsemaKJ, Van HoutMW, NilssonR, SillenH. A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4beta-hydroxycholesterol in human plasma. J. Pharm. Biomed. Anal. 55 (5), 1089–1095 (2011).
   PubMed Web of Science ®Google Scholar
• Tu J , BennettP. Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons. Bioanalysis9 (14), 1107–1122 (2017).
   PubMed Web of Science ®Google Scholar